Thomas van Es

CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice

Eva J.A. van Wanrooij, Saskia C.A. de Jager, Thomas van Es et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2007 · 123 citations · Full text

Life Sciences, Immunology, Pathobiology +17

IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice

Thomas van Es, Gijs H.M. van Puijvelde, Ingrid Michon et al. · Vaccine · 2010 · 43 citations · Full text

Life Sciences, Immunology, Pathobiology +17

Intradermal Delivery of TLR Agonists in a Human Explant Skin Model: Preferential Activation of Migratory Dendritic Cells by Polyribosinic-Polyribocytidylic Acid and Peptidoglycans

Dinja Oosterhoff, Moniek Heusinkveld, Sinéad M. Lougheed et al. · The Journal of Immunology · 2013 · 41 citations

Life Sciences, Cancer Biology, Immunology +16

A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine

Rolf J. Verheul, Niels Hagenaars, Thomas van Es et al. · European Journal of Pharmaceutical Sciences · 2011 · 14 citations

Pharmacy, Immunology, Molecular Pharmaceutics +16